XTX Topco Ltd decreased its holdings in Novartis AG (NYSE:NVS - Free Report) by 66.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,379 shares of the company's stock after selling 20,140 shares during the quarter. XTX Topco Ltd's holdings in Novartis were worth $1,010,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its position in Novartis by 35.6% during the fourth quarter. JPMorgan Chase & Co. now owns 423,142 shares of the company's stock worth $41,176,000 after buying an additional 111,066 shares in the last quarter. Foundations Investment Advisors LLC increased its position in shares of Novartis by 26.9% in the fourth quarter. Foundations Investment Advisors LLC now owns 89,074 shares of the company's stock worth $8,668,000 after purchasing an additional 18,894 shares during the period. CWA Asset Management Group LLC lifted its position in Novartis by 20.1% during the fourth quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company's stock worth $3,001,000 after purchasing an additional 5,164 shares during the period. Chicago Partners Investment Group LLC acquired a new stake in Novartis during the fourth quarter worth about $239,000. Finally, Arvest Bank Trust Division bought a new position in Novartis in the 3rd quarter valued at about $2,674,000. Institutional investors own 13.12% of the company's stock.
Wall Street Analyst Weigh In
Several analysts recently issued reports on the stock. UBS Group reissued a "neutral" rating on shares of Novartis in a research note on Thursday, February 13th. Barclays reiterated an "underweight" rating on shares of Novartis in a research note on Monday, February 3rd. Deutsche Bank Aktiengesellschaft upgraded Novartis from a "hold" rating to a "buy" rating in a research report on Tuesday, February 4th. BNP Paribas upgraded shares of Novartis to a "strong-buy" rating in a research report on Tuesday, April 15th. Finally, Morgan Stanley assumed coverage on shares of Novartis in a research note on Wednesday, February 12th. They set an "underweight" rating on the stock. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $123.38.
Check Out Our Latest Research Report on Novartis
Novartis Price Performance
NYSE NVS traded down $0.11 during trading on Monday, reaching $110.76. The company's stock had a trading volume of 268,253 shares, compared to its average volume of 1,552,924. Novartis AG has a one year low of $94.72 and a one year high of $120.92. The stock has a market capitalization of $226.38 billion, a PE ratio of 18.84, a P/E/G ratio of 1.70 and a beta of 0.56. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84. The firm has a fifty day moving average of $109.21 and a 200 day moving average of $106.22.
Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings data on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. Analysts expect that Novartis AG will post 8.45 EPS for the current fiscal year.
Novartis Dividend Announcement
The company also recently announced a dividend, which was paid on Wednesday, March 12th. Stockholders of record on Wednesday, March 12th were paid a $3.8695 dividend. The ex-dividend date was Wednesday, March 12th. Novartis's payout ratio is presently 42.69%.
About Novartis
(
Free Report)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Featured Articles
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
